Alnylam Pharmaceuticals, Inc. (ALNY) and GENESIS Pharma Expand Commercial Partnership
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the
12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On.
On June 10, GENESIS Pharma said it expanded its commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to include Denmark, Finland, Norway, and Sweden. It extension of a collaboration that began in Southeast Europe in 2019. It added marketing rights for RNAi therapies targeting cardiomyopathy and rare genetic diseases across the broader region. The company said the agreement now covers 17 markets and builds on an existing footprint across Greece, Romania, and other Southeast European countries. It plans to improve access in areas with unmet medical needs.
Separately, on June 3, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) said it formed a strategic artificial intelligence partnership with Inceptive Nucleics. The collaboration is valued at up to $2 billion, including $30 million upfront, merging its RNAi platform with Inceptive’s models to speed up drug discovery. CEO Yvonne Greenstreet said the partnership plans to “push the boundaries” of RNAi innovation, while Inceptive CEO Jakob Uszkoreit said the alliance could replace trial-and-error drug design with AI-powered approaches.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biopharmaceutical company that works in developing and marketing novel therapeutics based on ribonucleic acid interference.
While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
